Every GLP-1 Brand and Generic Available in 2026

The Complete 2026 GLP-1 Brand List

In 2026 there are seven FDA-approved GLP-1 receptor agonist medications, plus the compounded versions of those same active ingredients. Across them, four chemicals do the heavy lifting: semaglutide, tirzepatide, liraglutide, and dulaglutide.

Here's every GLP-1 brand on the market right now.

Brand-Name GLP-1 Medications

### Semaglutide brands

Ozempic (Novo Nordisk)

Wegovy (Novo Nordisk)

Rybelsus (Novo Nordisk)

### Tirzepatide brands

Mounjaro (Eli Lilly)

Zepbound (Eli Lilly)

### Liraglutide brands

Saxenda (Novo Nordisk)

Victoza (Novo Nordisk)

### Dulaglutide brand

Trulicity (Eli Lilly)

Quick Comparison Table

What Doesn't Make This List

You may have heard of these. They're not on the list because:

*Older GLP-1s (mostly retired or rarely used):*

*"GLP-1 patches" sold online:*

*"Natural Ozempic" supplements:*

Compounded GLP-1 Options

Compounded versions of the active ingredients above are dispensed by state-licensed compounding pharmacies. They use the same active pharmaceutical ingredient as brand-name medications at significantly lower cost.

*Compounded availability in 2026:*

Compounded medications aren't FDA-approved as final products, but the active ingredients are FDA-registered, and reputable 503A pharmacies third-party test every batch for potency and sterility.

Which One Should You Take?

The right choice depends on:

*Your goal:*

*Your dosing preference:*

*Your budget:*

*Your medical history:*

A real US-licensed physician will work through these factors with you in your initial consultation. The goal isn't to find the "best" GLP-1 in some absolute sense. It's to find the one that fits your situation.

The Bottom Line

There are seven brand-name GLP-1 medications in 2026. Most patients will benefit from one of: Wegovy, Zepbound, or compounded versions of semaglutide or tirzepatide. The other brands fit specific situations.

For a deeper dive on choosing between the most popular options, see our tirzepatide vs semaglutide guide and our Mounjaro vs Ozempic comparison.

What Changed in the GLP-1 Market in 2026 (June Update)

The list of molecules above is stable, but how people actually get GLP-1 medications shifted in the first half of 2026. Three changes matter if you are choosing a provider this year.

1. The compounding rules tightened. The FDA declared the semaglutide shortage resolved in February 2025 and the tirzepatide shortage resolved in late 2024. That ended the legal basis for compounding "essentially a copy" of the brand-name drugs. State-licensed 503A pharmacies can still prepare compounded GLP-1 medications when there is a documented clinical need for a customized formulation, such as a different concentration, a sublingual route, or an allergy adjustment, but the era of compounded injections marketed purely as a cheaper copy is over. Compounded medications are not FDA-approved as final products.

2. Two of the largest telehealth names stepped back from compounded semaglutide. During the first quarter of 2026, several high-profile direct-to-consumer telehealth brands exited or scaled back compounded semaglutide offerings and shifted toward brand-name fulfillment, partly in response to manufacturer legal pressure. The practical effect for patients is that the compounded market is now served by a smaller set of pharmacy-focused providers rather than the biggest consumer brands.

3. Brand-name self-pay prices dropped. Eli Lilly's LillyDirect now offers Zepbound single-dose vials in the $349 to $499 per month range, and Novo Nordisk runs a direct Wegovy program. These programs narrowed the gap between brand-name and compounded pricing compared with 2023 and 2024, when the difference could exceed 80 percent.

The takeaway: the molecules have not changed, but in 2026 the decision is less about "brand versus a cheap copy" and more about which legitimate, licensed pathway fits your clinical situation and budget.

Related guides